BC Week In Review | Jun 22, 2017
Clinical News

Affiris' Affitope PD03A well tolerated in Phase I to treat early PD

Affiris AG (Vienna, Austria) reported top-line data from a single-blind, placebo-controlled, Austrian Phase I AFF011 trial in 36 patients with early Parkinson’s disease (PD) showing that 15 and 75 µg doses of subcutaneous Affitope PD03A...
BC Extra | Mar 21, 2015
Clinical News

Prothena soars on Phase I Parkinson's data

Prothena Corp. plc (NASDAQ:PRTA) rose $9.43 (32%) to $38.66 on Friday after it said Parkinson's disease (PD) candidate PRX002 reduced free serum alpha synuclein ( SNCA ) levels by up to 96% in a Phase I trial...
BC Innovations | Mar 19, 2015
Targets & Mechanisms

Untangling α-synuclein

The Michael J. Fox Foundation for Parkinson's Research (MJFF) wants to settle the question of what form of α-synuclein drives the pathology of Parkinson's disease. To make sure the data hold up in different labs...
BC Week In Review | Jan 5, 2015
Clinical News

Affitope PD03A: Phase I started

Affiris and the SYMPATH consortium began the single-blind, placebo-controlled, Austrian Phase I AFF011 trial to evaluate 4 injections of 15 and 75 µg subcutaneous Affitope PD03A plus an adjuvant every 4 weeks in about 36...
BC Week In Review | May 5, 2014
Company News

Affiris, Biolution GmbH, Forschungszentrum Juelich GmbH, French Clinical Research Infrastructure Network (F-Crin), Medical University Innsbruck, Prosenex Ambula

The SYMPATH consortium received €6 million ($8.3 million) under the EU's Seventh Framework Programme (FP7). The consortium, which will run for 48 months, is developing two vaccine candidates from Affiris against Parkinson's disease and multiple...
Items per page:
1 - 5 of 5